Astrana Health (ASTH) has been drawing fresh attention after its recent rebrand from Apollo Medical Holdings, shifting its identity while continuing to focus on healthcare management and coordination across Medicare, Medicaid and commercially insured patients.

The recent rebrand comes against a mixed backdrop, with a 30 day share price return of 20.65% contrasting with a 1 year total shareholder return decline of 20.36%. This suggests shorter term momentum while longer term holders have seen weaker results.

If this kind of rebound catches your eye, it may be worth scanning other healthcare names using our 34 healthcare AI stocks as a starting list of ideas.

With Astrana posting annual revenue and net income growth alongside a discount of about 46% to the average analyst price target and an indicated intrinsic discount of roughly 77%, you have to ask: is this a mispriced healthcare operator, or is the market already baking in all the future gains?

Most Popular Narrative: 34.8% Undervalued

With Astrana's fair value estimate at about $35.67 versus the last close at $23.25, the most widely followed narrative sees a sizeable valuation gap that hinges on execution over the next few years.

Recent research updates show analysts reassessing Astrana Health's potential as they wait for clearer evidence on full risk contract conversions and Medicare Advantage performance in 2026. Price targets have been adjusted, but the core debate centers on execution timing and how much value investors should attach to longer term opportunities.

Curious what kind of revenue growth, margin uplift and future earnings multiple have to come together to support that higher fair value? The full narrative lays out a detailed roadmap built around value based contracts, Medicare Advantage assumptions and how much investors might eventually pay for those projected earnings.

Result: Fair Value of $35.67 (UNDERVALUED)

However, there is still meaningful risk that heavy reliance on Medicare and Medicaid reimbursement, along with execution hurdles around full risk contract conversions, could undercut that upside story.

Another Angle On The Valuation

The first story paints Astrana as undervalued, with the share price at $23.25 compared with a fair value estimate of $35.67 and even a DCF based future cash flow value of $102.64. Yet on a simple P/E of 50.5x versus a fair ratio of 35.6x, the stock screens as expensive. Which signal do you respect more?

Next Steps

If the mix of upside and concern feels hard to weigh, check the numbers for yourself and move quickly to form your own stance with 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Astrana has sparked your interest, do not stop here. Use focused stock lists to spot other opportunities that could suit your style before the crowd catches on.

• Target reliable income by scanning companies that show up in our 15 dividend fortresses and see which payouts might fit a long term portfolio.
• Hunt for value by reviewing our 48 high quality undervalued stocks, a list built to highlight companies trading at prices that may not fully reflect their fundamentals.
• Prioritize resilience by checking the 68 resilient stocks with low risk scores and focus on businesses with risk profiles that could better match a more cautious approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.